H. pylori prospective treatment for asymptomatic ulcer patients is cost-effective, study says.
H. PYLORI ERADICATION FOR ASYMPTOMATIC DUODENAL ULCER PATIENTS who are controlled on maintenance therapy is recommended in a pharmacoeconomic study by Mark Fendrick, MD, et al. of the University of Michigan, presented May 14 at the Association for Pharmacoeconomics & Outcomes Research annual meeting in Philadelphia. "Based on the clinical and economic outcomes, patients with documented peptic ulcers not previously eradicated for H. pylori should be promptly identified and treated," Fendrick declared.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth